Electrocore LLC
$ 5.00
5.26%
03 Dec - close price
- Market Cap 39,979,500 USD
- Current Price $ 5.00
- High / Low $ 5.00 / 4.74
- Stock P/E N/A
- Book Value -0.14
- EPS -1.71
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.39 %
- ROE -3.38 %
- 52 Week High 19.49
- 52 Week Low 4.16
About
Electrocore, Inc. is a commercial-stage medical device company based in Rockaway, New Jersey, specializing in non-invasive vagus nerve stimulation (nVNS) therapies aimed at treating neurological disorders such as chronic pain, migraine, and epilepsy. By leveraging its innovative product portfolio and strong clinical evidence, Electrocore is positioned as a leader in the neuromodulation market, demonstrating a robust commitment to improving patient outcomes. The company's focus on advancing non-invasive therapeutic solutions highlights its potential to significantly enhance the quality of life for patients grappling with debilitating neurological conditions.
Analyst Target Price
$21.14
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-06 | 2025-05-06 | 2025-03-11 | 2024-11-13 | 2024-08-07 | 2024-05-08 | 2024-03-13 | 2023-11-08 | 2023-08-09 | 2023-05-03 | 2023-03-08 |
| Reported EPS | -0.4 | -0.44 | -0.47 | -0.4 | -0.31 | -0.38 | -0.52 | -0.61 | -0.68 | -1.03 | -1.24 | -1.22 |
| Estimated EPS | -0.4 | -0.15 | -0.4467 | -0.3 | -0.33 | -0.44 | -0.62 | -0.61 | -0.7 | -0.96 | -1 | -1.12 |
| Surprise | 0 | -0.29 | -0.0233 | -0.1 | 0.02 | 0.06 | 0.1 | 0 | 0.02 | -0.07 | -0.24 | -0.1 |
| Surprise Percentage | 0% | -193.3333% | -5.216% | -33.3333% | 6.0606% | 13.6364% | 16.129% | 0% | 2.8571% | -7.2917% | -24% | -8.9286% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ECOR
2025-10-23 12:21:00
electroCore, Inc. (ECOR) will report its Q3 2025 financial results on November 5, 2025, after market close, followed by a webinar. The company, which focuses on bioelectronic technologies for chronic pain and wellness, will provide an update on its performance and answer investor questions. Insider trading activity and institutional holdings data for ECOR are also detailed.
2025-09-29 08:00:00
electroCore, Inc. announced that its gammaCore™ Sapphire (nVNS) device has received long-term reimbursement approval from RIZIV/INAMI in Belgium, effective October 1, 2025. This policy covers the treatment of cluster headaches and is based on strong clinical evidence of its efficacy and cost-effectiveness. The approval, facilitated by electroCore’s distribution partner Silvert Medical, is expected to significantly increase access to this therapy for Belgian patients.
2025-08-24 00:00:00
electroCore, Inc. (NASDAQ:ECOR) shares have fallen 27% in the last month, bringing its annual return to -5.8%. Despite a low price-to-sales (P/S) ratio of 1.5x compared to the industry average of 2.9x, the article suggests potential underlying risks, especially given its strong revenue growth and positive analyst forecasts that don't align with its low P/S. The company has shown exceptional revenue growth but shareholders appear doubtful about future forecasts.
2025-05-18 00:00:00
electroCore, Inc. is projected to become profitable around 2027, according to analysts, after incurring a recent loss of US$12m. The company needs to achieve an average annual growth rate of 62% to hit this breakeven point. Notably, electroCore operates without debt, reducing financial risk despite being a cash-burning growth company.
2025-05-02 08:00:00
electroCore, Inc. has completed its acquisition of NeuroMetrix, Inc., integrating NeuroMetrix's Quell platform to broaden electroCore’s bioelectronic technology portfolio. This merger is expected to accelerate growth in the chronic pain and wellness markets, particularly within the VA Hospital System, and strengthen electroCore's position as a leader in non-invasive bioelectronic solutions. NeuroMetrix stockholders received $4.49 per share in cash and one contingent value right (CVR) for future sales milestones and disposition proceeds.
2024-12-31 23:59:59
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NeuroMetrix, Inc. (NASDAQ: NURO) to electroCore, Inc. is fair to NeuroMetrix shareholders. The investigation will assess whether NeuroMetrix and its board obtained the best possible consideration, if electroCore is underpaying, and if all material information was disclosed for shareholders to value the merger. Halper Sadeh LLC is encouraging shareholders to contact them to learn about their legal rights and options regarding the transaction.
